Crigler-Najjar综合征与UGT1A1基因突变的研究进展

闫悦 综述; 李亚绒

doi:10.11852/zgetbjzz2019-1420

PDF(480 KB)

中国儿童保健杂志 ›› 2020, Vol. 28 ›› Issue (8) : 887-889. DOI: 10.11852/zgetbjzz2019-1420

综述

Crigler-Najjar综合征与UGT1A1基因突变的研究进展

闫悦¹ 综述, 李亚绒² (审校)

作者信息 +

Review on Crigler-Najjar syndrome and uridine diphosphate glucuronosyl transferase 1A1 gene mutation

YAN Yue, LI Ya-rong

Author information +

文章历史 +

摘要

Crigler-Najjar综合征(CNS)是先天性、非梗阻性、非溶血性、高未结合胆红素血症。其特征是肝细胞完全或接近完全缺乏尿嘧啶二磷酸葡萄糖醛基转移酶1A1(UGT1A1)。CNS的诊断主要是根据临床表现及实验室检查初步诊断, 之后可结合基因检测、胆汁成分分析、肝组织中UGT1A1酶活性测定等方法进行确诊。CNS及UGT1A1基因多态性在多种药物代谢及多种疾病的发病中有重要的意义, 即使其作用机制及具体影响没有一个定性及定量的评定, 但明确诊断后对于临床的指导意义很大。本文就CNS的临床诊治以及UGT1A1基因突变之间的关系进行综述。

Abstract

Crigler-Najjar Syndrome (CNS) is congenital, non-obstructive, non-hemolytic, hyperunbound bilirubinemia, which is characterized by a completed or near-total deficiency of uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1) in liver cells.The preliminary diagnosis of CNS is mainly based on clinical manifestations and laboratory examination.After that, the diagnosis can be made by combining genetic testing, analysis of bile components and determination of UGT1A1 activity in liver tissues.CNS and UGT1A1 gene polymorphisms are of great significance in the metabolism of multiple drugs and the pathogenesis of multiple diseases.Even if the mechanism and specific effects of the genes are not qualitatively and quantitatively evaluated, clear diagnosis is of great significance for clinical guidance.This review summarizes the clinical diagnosis and treatment of CNS and the relationship between UGT1A1 gene mutations and CNS.

导出引用

闫悦综述, 李亚绒. Crigler-Najjar综合征与UGT1A1基因突变的研究进展[J]. 中国儿童保健杂志. 2020, 28(8): 887-889 https://doi.org/10.11852/zgetbjzz2019-1420

YAN Yue, LI Ya-rong. Review on Crigler-Najjar syndrome and uridine diphosphate glucuronosyl transferase 1A1 gene mutation[J]. Chinese Journal of Child Health Care. 2020, 28(8): 887-889 https://doi.org/10.11852/zgetbjzz2019-1420

中图分类号： :R725.9

参考文献

[1] 潘丽丽.Crigler-Najjar综合征Ⅱ型UGT1A1基因突变分析[D].太原;山西医科大学, 2013:1-47.
[2] 伍玉南, 彭建平, 黄裕红, 等.Ⅱ型Crigler-Najjar综合征1例报告[J].临床肝胆病杂志, 2016, 32(4):776-778.
[3] Junko S.Function, genetic polymorphism, and transcriptional regulation of human UDP-glucuronosyltransferase(UGT)1A1[J].Drug Metab Pharmacokinet, 2013, 28(2):83-92.
[4] 何志颖, 尤红, 赵新颜.成人期遗传代谢性肝病的临床及病理特点[J].中华肝脏病杂志, 2018, 26(12):889-893.
[5] Sappal BS, Ghosh SS, Shneider B, et al.A novel intronic mutation results in the use of a cryptic splice acceptor site within the coding region of UGT1A1, causing Crigler-Najjar syndrome type[J].Mol Genet Metab, 2002, 75(2):134-142.
[6] 吴运芹, 李贵南, 周勇, 等.一例Crigler-Najjar综合征Ⅱ型患儿的基因突变分析[J].中华医学遗传学杂志, 2016, 33(3):328.
[7] Hamid H, Hamid H, Farhad L, et al.Cost-effectiveness analysis of topiramate versus phenobarbital in the treatment of children with febrile seizure[J].J Child Neurol, 2019, 13(4):109-120.
[8] Kummer O, Hammann F, Haschke M, et al.Reduction of hyperbilirubinemia with hypericum extract (St.John's Wort) in a patient with Crigler-Najjar syndrome type II[J].Br J Clin Pharmacol, 2016, 81(5):1002-1004.
[9] Ebrahimi A, Rahim F.Crigler-Najjar syndrome:current perspectives and the application of clinical genetics[J].Endocr Metab Immune Disord Drug Targets, 2018, 18(3):201-211.
[10] Meyburg J, Schmidt J, Hoffmann GF.Liver cell transplantation in children[J].Clin Transplant, 2009, 23(Suppl 21):75-82.
[11] Broering DC, Walter J, Bassas AF.Overcoming the portal steal phenomenon in auxiliary partial orthotopic liver transplantation by modulation of the venous outflow of the native liver[J].Liver Transpl, 2005, 11(9):1140-1143.
[12] Bortolussi G, Zentillin L, Jana V, et al.Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of Crigler-Najjar syndrome[J].Hum Gene Ther, 2014, 25(9):845-855.
[13] Greig JA, Nordin J, Draper C, et al.AAV8 Gene therapy rescues the newborn phenotype of a mouse model of Crigler-Najjar[J].Hum Gene Ther, 2018, 29(7):763-770.
[14] Apgar JF, Tang JP, Singh P, et al.A quantitative systems pharmacology model of UGT1A1-modRNA encoding for the UGT1A1 enzyme to Treat Crigler-Najjar syndrome type 1[J].CPT Pharmacometrics Syst Pharmacol, 2018, 7(6):404-412.
[15] 韦小兰, 骆子义.新生儿不明原因高胆红素血症与UGT1A1基因多态性的研究进展[J].实用临床医学, 2017, 18(1):101-105.
[16] 刘雪梅, 骆子义.Gilbert综合征及Crigler-Najjar综合征诊断方法[J].分子诊断与治疗杂志, 2016, 8(3):201-205.
[17] 车芳, 骆子义.UGT1A1基因在Gilbert综合征及Crigler-Najjar综合征发病机制中研究进展[J].中华实用诊断与治疗杂志, 2015, 29(3):219-222.
[18] Canu G, Minucci A, Zuppi C, et al.Gilbert and Crigler Najjar syndromes:An update of the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene mutation database[J].Blood Cells Mol Dis, 2013, 50(4):273-280.
[19] Maruo Y, Nakahara S, Yanagi T, et al.Genotype of UGT1A1 and phenotype correlation between Crigler-Najjar syndrome type Ⅱ and Gilbert syndrome[J].J Gastroenterol Hepatol, 2016, 31(2):403-408.
[20] Sun L, Li M, Zhang L, et al.Differences in UGT1A1 gene mutations and pathological liver changes between Chinese patients with Gilbert syndrome and Crigler-Najjar syndrome type Ⅱ[J].Medicine, 2017, 96(45):e8620.
[21] Yan LI, Yu-Jin QU, Zhong XM, et al.Two unrelated patients with rare Crigler-Najjar syndrome type Ⅰ:two novel mutations and a patient with loss of heterozygosity of UGT1A1 gene[J].J Zhejiang Univ Sci B, 2014, 15(5):474-481.

[22] Chou HC, Chen MH, Yang HI, et al.211 G to a variation of UDP-glucuronosyl transferase 1A1 gene and neonatal breastfeeding jaundice[J].Pediatr Res, 2011, 69(2):170-174.
[23] Sato H, Uchida T, Toyota K, et al.Association of breast-fed neonatal hyperbilirubinemia with UGT1A1 polymorphisms:211G＞A (G71R) mutation becomes a risk factor under inadequate feeding[J].J Hum Genet 2013, 58(1):7-10.
[24] 李淑芬, 阿依先木, 王然, 等.新疆维、汉族新生儿高胆红素血症与UGT1A1基因G71R多态性的关联性研究[J].中国儿童保健杂志, 2017, 25(2):121-123, 146.
[25] Nakagawa T, Mure T, Yusoff S, et al.A homozygous mutation in UGT1A1 exon 5 may be responsible for persistent hyperbilirubinemia in a Japanese girl with Gilbert's syndrome[J].Kobe J Med Sci, 2011, 57(1):e26-e31.
[26] 冯于玲, 高宗燕, 刘义, 等.Crigler-NajjarⅠ型综合征患者及其家系UGT1A1基因的遗传分析[J].中华实用儿科临床杂志, 2014, 29(11):847-850.